PMID- 37511291
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20230801
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 14
DP  - 2023 Jul 16
TI  - Intratumor Heterogeneity and Treatment Resistance of Solid Tumors with a Focus on 
      Polyploid/Senescent Giant Cancer Cells (PGCCs).
LID - 10.3390/ijms241411534 [doi]
LID - 11534
AB  - Single cell biology has revealed that solid tumors and tumor-derived cell lines 
      typically contain subpopulations of cancer cells that are readily distinguishable 
      from the bulk of cancer cells by virtue of their enormous size. Such cells with a 
      highly enlarged nucleus, multiple nuclei, and/or multiple micronuclei are often 
      referred to as polyploid giant cancer cells (PGCCs), and may exhibit features of 
      senescence. PGCCs may enter a dormant phase (active sleep) after they are formed, 
      but a subset remain viable, secrete growth promoting factors, and can give rise 
      to therapy resistant and tumor repopulating progeny. Here we will briefly discuss 
      the prevalence and prognostic value of PGCCs across different cancer types, the 
      current understanding of the mechanisms of their formation and fate, and possible 
      reasons why these tumor repopulating "monsters" continue to be ignored in most 
      cancer therapy-related preclinical studies. In addition to PGCCs, other 
      subpopulations of cancer cells within a solid tumor (such as oncogenic caspase 
      3-activated cancer cells and drug-tolerant persister cancer cells) can also 
      contribute to therapy resistance and pose major challenges to the delivery of 
      cancer therapy.
FAU - Mirzayans, Razmik
AU  - Mirzayans R
AD  - Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, 
      AB T6G 1Z2, Canada.
FAU - Murray, David
AU  - Murray D
AD  - Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, 
      AB T6G 1Z2, Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230716
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
SB  - IM
MH  - Humans
MH  - *Neoplasms/drug therapy/genetics/metabolism
MH  - Giant Cells/metabolism
MH  - Polyploidy
PMC - PMC10380821
OTO - NOTNLM
OT  - anastasis
OT  - apoptosis
OT  - cancer therapy
OT  - intratumor heterogeneity
OT  - polyploid giant cancer cells
OT  - precision oncology
OT  - preclinical assays
OT  - senescence
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/29 11:48
MHDA- 2023/07/31 06:42
PMCR- 2023/07/16
CRDT- 2023/07/29 01:23
PHST- 2023/07/02 00:00 [received]
PHST- 2023/07/14 00:00 [revised]
PHST- 2023/07/14 00:00 [accepted]
PHST- 2023/07/31 06:42 [medline]
PHST- 2023/07/29 11:48 [pubmed]
PHST- 2023/07/29 01:23 [entrez]
PHST- 2023/07/16 00:00 [pmc-release]
AID - ijms241411534 [pii]
AID - ijms-24-11534 [pii]
AID - 10.3390/ijms241411534 [doi]
PST - epublish
SO  - Int J Mol Sci. 2023 Jul 16;24(14):11534. doi: 10.3390/ijms241411534.